Abels R I
Biotech Division, Robert Wood Johnson Pharmaceutical Research Institute, Raritan, NJ 08869.
Semin Oncol. 1992 Jun;19(3 Suppl 8):29-35.
Mild to moderate anemia associated with malignant disease can contribute to the overall morbidity in patients with cancer. Because this anemia has been linked to a blunted erythropoietin response, recombinant human erythropoietin (r-HuEPO) was assessed as a means to correct it and provide some degree of palliation. Three different patient populations were studied: one population not administered chemotherapy, a second population administered chemotherapy that did not include cisplatin, and a third population administered chemotherapy that included cisplatin. In all patient populations, r-HuEPO increased hematocrit values compare with placebo. In the two chemotherapy-treated populations, r-HuEPO decreased blood transfusion requirements after the first month of therapy. Patient-rated energy levels, ability to engage in daily activity, and overall quality of life improved in patients who responded to r-HuEPO therapy with an increase in hematocrit values of 6 percentage points or more. Thus, it appears that r-HuEPO may be a useful adjunct for palliation and treatment of anemia in patients with cancer.
与恶性疾病相关的轻至中度贫血会加重癌症患者的整体发病率。由于这种贫血与促红细胞生成素反应减弱有关，因此对重组人促红细胞生成素（r-HuEPO）进行了评估，以纠正贫血并提供一定程度的缓解。研究了三个不同的患者群体：一个未接受化疗的群体，第二个接受不包括顺铂的化疗的群体，以及第三个接受包括顺铂的化疗的群体。在所有患者群体中，与安慰剂相比，r-HuEPO提高了血细胞比容值。在两个接受化疗的群体中，r-HuEPO在治疗第一个月后降低了输血需求。血细胞比容值增加6个百分点或更多的患者对r-HuEPO治疗有反应，其自我评估的能量水平、参与日常活动的能力和总体生活质量均有所改善。因此，r-HuEPO似乎可能是癌症患者贫血缓解和治疗的有用辅助手段。
